The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be ...

Please provide your email address to receive an email when new articles are posted on . The FDA today approved the chemotherapy drug eribulin mesylate for the treatment of patients with unresectable ...

The approval of Halaven was based on an improvement in overall survival (OS) in a phase 3 study. The FDA has approved Halaven (eribulin mesylate) as a treatment for patients with advanced or ...

The Food and Drug Administration (FDA) has approved Halaven (eribulin mesylate; Eisai) for the treatment of unresectable or metastatic liposarcoma in patients who have received prior chemotherapy ...

NICE has said Eisai’s breast cancer drug Halaven should not be funded by the NHS in a new use, its first draft guidance citing uncertainty in the clinical evidence submitted. Eisai already has a ...

(Corrects paragraph 1 in Jan. 28 story to drop words "which has no approved treatment so far") Jan 28 (Reuters) - The U.S. Food and Drug Administration approved Eisai Co Ltd's drug derived from sea ...

Eisai may have to sell its Halaven (eribulin) at rock-bottom prices in its new advanced liposarcoma use in Germany after a cost-effectiveness body found it offered “no additional benefit” compared ...

The $16,000 treatment Halaven is based on chemicals from a sea sponge, stops cancer cells dividing and can extend the life of women with advanced breast cancer by an average two-and-a-half months.

Merck & Co., Inc. MRK and partner Eisai Co., Ltd. ESALY announced new interim data from a phase Ib/II study on the Keytruda-Halaven combination for the treatment of metastatic triple-negative breast ...

Eisai has launched its oncology product Halaven in Russia for the treatment of women with metastatic breast cancer. Halaven (eribulin) will be available for patients who have already had treatment ...

The U.S. Food and Drug Administration approved Eisai Co Ltd's drug derived from sea sponge for a rare type of soft tissue cancer which has no approved treatment so far. The drug, Halaven, was approved ...